Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 14 studies | 31% ± 14% | |
peripheral blood | 12 studies | 25% ± 10% | |
brain | 9 studies | 30% ± 12% | |
intestine | 9 studies | 29% ± 16% | |
kidney | 8 studies | 31% ± 11% | |
liver | 8 studies | 30% ± 21% | |
eye | 7 studies | 29% ± 11% | |
pancreas | 4 studies | 41% ± 17% | |
placenta | 4 studies | 37% ± 23% | |
bone marrow | 4 studies | 23% ± 6% | |
uterus | 4 studies | 33% ± 15% | |
breast | 4 studies | 25% ± 7% | |
adrenal gland | 3 studies | 24% ± 5% | |
skin | 3 studies | 24% ± 6% | |
thymus | 3 studies | 52% ± 26% | |
lymph node | 3 studies | 30% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4308.76 | 1445 / 1445 | 100% | 179.34 | 183 / 183 |
kidney | 100% | 4988.73 | 89 / 89 | 100% | 201.40 | 901 / 901 |
liver | 100% | 4702.37 | 226 / 226 | 100% | 205.57 | 406 / 406 |
ovary | 100% | 3987.03 | 180 / 180 | 100% | 175.78 | 430 / 430 |
pancreas | 100% | 3210.06 | 328 / 328 | 100% | 190.34 | 178 / 178 |
prostate | 100% | 4107.66 | 245 / 245 | 100% | 251.32 | 502 / 502 |
skin | 100% | 6721.41 | 1809 / 1809 | 100% | 303.15 | 472 / 472 |
stomach | 100% | 3644.74 | 359 / 359 | 100% | 201.14 | 286 / 286 |
uterus | 100% | 4165.55 | 170 / 170 | 100% | 292.14 | 459 / 459 |
brain | 100% | 4563.65 | 2639 / 2642 | 100% | 256.46 | 705 / 705 |
breast | 100% | 4769.24 | 459 / 459 | 100% | 234.70 | 1115 / 1118 |
thymus | 100% | 3665.32 | 652 / 653 | 100% | 192.98 | 604 / 605 |
lung | 100% | 3960.16 | 576 / 578 | 100% | 198.88 | 1155 / 1155 |
intestine | 100% | 4037.07 | 966 / 966 | 100% | 231.64 | 525 / 527 |
adrenal gland | 100% | 6815.62 | 258 / 258 | 100% | 206.46 | 229 / 230 |
bladder | 100% | 4115.10 | 21 / 21 | 99% | 232.32 | 501 / 504 |
adipose | 100% | 4693.59 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 322.98 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 318.19 | 29 / 29 |
muscle | 100% | 6446.21 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3716.12 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 315.55 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 173.16 | 1 / 1 |
blood vessel | 100% | 4221.72 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 4791.82 | 849 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 3497.33 | 905 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0000502 | Cellular component | proteasome complex |
GO_0034774 | Cellular component | secretory granule lumen |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0005839 | Cellular component | proteasome core complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0016604 | Cellular component | nuclear body |
GO_0005576 | Cellular component | extracellular region |
GO_0019774 | Cellular component | proteasome core complex, beta-subunit complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004175 | Molecular function | endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004298 | Molecular function | threonine-type endopeptidase activity |
Gene name | PSMB7 |
Protein name | Proteasome subunit beta Proteasome subunit beta type-7 (EC 3.4.25.1) (Macropain chain Z) (Multicatalytic endopeptidase complex chain Z) (Proteasome subunit Z) |
Synonyms | Z |
Description | FUNCTION: Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB7 displays a trypsin-like activity. . FUNCTION: Component of the proteasome, a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. . FUNCTION: Component of the proteasome, a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. . |
Accessions | Q5TBG5 ENST00000441097.1 Q6IBT1 ENST00000259457.8 [Q99436-1] Q99436 |